Lineage Cell Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Lineage Cell Therapeutics has a total shareholder equity of $71.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $108.5M and $37.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$43.62m |
| Equity | US$70.99m |
| Total liabilities | US$37.49m |
| Total assets | US$108.48m |
Financial Position Analysis
Short Term Liabilities: LCTX's short term assets ($45.7M) exceed its short term liabilities ($16.9M).
Long Term Liabilities: LCTX's short term assets ($45.7M) exceed its long term liabilities ($20.6M).
Debt to Equity History and Analysis
Debt Level: LCTX is debt free.
Reducing Debt: LCTX has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LCTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LCTX has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 12.3% each year.